Moderna, Inc. Common Stock
MRNAModerna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA (mRNA) technology to develop vaccines and therapeutics. Founded in 2010, it gained prominence with its COVID-19 vaccine, playing a key role in the global response to the pandemic. Moderna focuses on innovative mRNA solutions for infectious diseases, cancer, rare diseases, and other conditions.
Company News
U.S. stock futures rose on Thursday following Wednesday's gains, with major indices climbing over 1% after President Trump withdrew planned EU tariffs following a meeting with NATO Secretary General Mark Rutte. Key stocks in focus include Intel reporting quarterly earnings, Microsoft announcing a partnership with Mercedes-AMG PETRONAS F1 Team, Mo...
Moderna shares surged 7.19% to $46.09 following positive five-year follow-up data from its partnership with Merck on an experimental personalized cancer vaccine (intismeran autogene). The mRNA-based therapy combined with Keytruda demonstrated a 49% reduction in melanoma recurrence risk, maintaining benefits observed at three-year follow-up. The r...
U.S. stocks rebounded cautiously on Wednesday following Trump's remarks at Davos regarding Greenland as a national security priority. The market showed restraint with the Dow up 0.6%, while the oil and gas sector surged due to forecasts of an Arctic blast. Natural gas futures jumped nearly 24%, marking the largest two-day gain on record. Mixed ea...
Moderna shares jumped 17% on January 13, 2026, after the company raised its 2025 revenue guidance to $1.9 billion and announced significant cost reductions. However, the stock remains down 90% from its all-time high, with COVID vaccine revenue declining sharply from $7.2 billion quarterly in late 2021 to $971 million in the last quarter. The comp...
Moderna and Merck announced five-year follow-up data from their Phase 2b study of intismeran autogene (mRNA-4157/V940) combined with Keytruda for high-risk melanoma. The combination therapy demonstrated sustained clinical benefit, reducing recurrence or death risk by 49% compared to Keytruda alone. Multiple Phase 3 trials are underway for melanom...
